EXHIBIT 10.2
EXECUTION VERSION
PSS World Medical,
Inc.
3.125% Convertible Senior Notes
due August 1, 2014
Purchase
Agreement
July 29, 2008
Goldman, Sachs &
Co.,
85 Broad Street,
New York, New York 10004
Ladies and Gentlemen:
PSS World Medical, Inc., a Florida
corporation (the “Company”), proposes, subject to the
terms and conditions stated herein, to issue and sell to Goldman,
Sachs & Co. (the “Purchaser”) an aggregate of
$200,000,000 principal amount of the Convertible Senior Notes due
August 1, 2014, convertible into common stock, par value $0.01
(“Stock”), of the Company, specified above (the
“Firm Securities”) and, at the election of the
Purchaser, up to an aggregate of $30,000,000 additional aggregate
principal amount (the “Optional Securities”) (the Firm
Securities and the Optional Securities which the Purchaser elects
to purchase pursuant to Section 2 hereof are herein
collectively called the “Securities”). In connection
with the offering of the Securities, the Company is entering into
convertible note hedge and warrant transactions with Goldman,
Sachs & Co. (the “Convertible Note Hedge and Warrant
Counterparty”) pursuant to confirmation letters, dated
July 29, 2008, subject to an agreement in the form of the ISDA
2002 Master Agreement (collectively, the “Convertible Note
Hedge and Warrant Transaction Documentation”, and the
confirmation letter relating to the convertible note hedge
transaction, the “Convertible Note Hedge Confirmation”
and the confirmation letter relating to the warrant transaction,
the “Warrant Confirmation”).
|
1.
|
The Company represents and
warrants to, and agrees with, the Purchaser that:
|
|
|
(a)
|
A preliminary offering circular,
dated July 28, 2008 (the “Preliminary Offering
Circular”), and an offering circular, dated July 29,
2008 (the “Offering Circular”), have been prepared in
connection with the offering of the Securities and the shares of
Stock issuable upon conversion thereof. The Preliminary Offering
Circular, as amended and supplemented immediately prior to the
Applicable Time (as defined in Section 1(b)), is hereinafter
referred to the “Pricing Circular”. Any reference to
the Preliminary Offering Circular, the Pricing Circular or the
Offering Circular shall be deemed to refer to and include the
Company’s most recent Annual Report on Form 10-K and all
subsequent documents filed with the United States Securities and
Exchange Commission (the “Commission”) pursuant to
Section 13(a), 13(c), 14 or 15(d) of the United States
Securities Exchange Act of 1934, as amended (the “Exchange
Act”) on or prior to the date of such circular and any
reference to the Preliminary Offering Circular, the Pricing
Circular or the Offering Circular, as the case may be,
as
|
|
|
amended or supplemented, as of
any specified date, shall be deemed to include (i) any
documents filed with the Commission pursuant to Section 13(a),
13(c), 14 or 15(d) of the Exchange Act after the date of the
Preliminary Offering Circular, the Pricing Circular or the Offering
Circular, as the case may be, and prior to such specified date and
(ii) any Additional Issuer Information (as defined in
Section 5(f)) furnished by the Company prior to the completion
of the distribution of the Securities; and all documents filed
under the Exchange Act and so deemed to be included in the
Preliminary Offering Circular, the Pricing Circular or the Offering
Circular, as the case may be, or any amendment or supplement
thereto are hereinafter called the “Exchange Act
Reports”. The Exchange Act Reports, when they were or are
filed with the Commission, conformed or will conform in all
material respects to the applicable requirements of the Exchange
Act and the applicable rules and regulations of the Commission
thereunder; and no such documents were filed with the Commission
since the Commission’s close of business on the business day
immediately prior to the date of this Agreement and prior to the
execution of this Agreement, except as set forth on
Schedule I(a) hereof. The Preliminary Offering Circular or the
Offering Circular and any amendments or supplements thereto and the
Exchange Act Reports did not and will not, as of their respective
dates, contain an untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were
made, not misleading; provided , however , that this
representation and warranty shall not apply to any statements or
omissions made in reliance upon and in conformity with information
furnished in writing to the Company by the Purchaser for use
therein;
|
|
|
(b)
|
For the purposes of this
Agreement, the “Applicable Time” is 5:30 p.m. (Eastern
time) on the date of this Agreement; the Pricing Circular as
supplemented by the information set forth in Schedule II hereto,
taken together (collectively, the “Pricing Disclosure
Package”) as of the Applicable Time, did not include any
untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not
misleading; and each Company Supplemental Disclosure Document (as
defined in Section 6(a)) listed on Schedule I(b) hereto
does not conflict with the information contained in the Pricing
Circular or the Offering Circular and each such Company
Supplemental Disclosure Document, as supplemented by and taken
together with the Pricing Disclosure Package as of the Applicable
Time, did not include any untrue statement of a material fact or
omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which
they were made, not misleading; provided, however, that this
representation and warranty shall not apply to statements or
omissions made in a Company Supplemental Disclosure Document in
reliance upon and in conformity with information furnished in
writing to the Company by the Purchaser expressly for use
therein;
|
|
|
(c)
|
Neither the Company nor any of
its subsidiaries has sustained since the date of the latest audited
financial statements included or incorporated by reference in the
Pricing Circular any material loss or interference with its
business from fire, explosion, flood or other calamity, whether or
not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, otherwise than as set forth
or contemplated in the Pricing Circular; and, since the respective
dates as of which information is given in the Pricing Circular,
there has not been any change in the capital stock or long-term
debt of the Company or any of its subsidiaries (other than stock
option transactions, normal debt payments and other such
|
2
|
|
transactions in the normal course
of business) or any material adverse change, or any development
involving a prospective material adverse change (other than general
economic and industry conditions that would not disproportionately
affect the Company), in or affecting the general affairs,
management, financial position, shareholders’ equity or
results of operations of the Company and its subsidiaries,
otherwise than as set forth or contemplated in the Pricing
Circular;
|
|
|
(d)
|
The Company and its subsidiaries
have good and marketable title in fee simple to all real property
and good and marketable title to all material personal property
owned by them, in each case free and clear of all liens,
encumbrances and defects except (i) as set forth in the
Pricing Circular, or (ii) as do not materially affect the
value of such property and do not interfere with the use made and
proposed to be made of such property by the Company and its
subsidiaries; and any real property and buildings held under lease
by the Company and its subsidiaries are held by them under valid,
subsisting and enforceable leases with such exceptions as are not
material and do not interfere with the use made and proposed to be
made of such property and buildings by the Company and its
subsidiaries;
|
|
|
(e)
|
The Company (i) has been
duly incorporated and is validly existing as a corporation in good
standing under the laws of the State of Florida, with power and
authority (corporate and other) to own its properties and conduct
its business as described in the Pricing Circular, and
(ii) has been duly qualified as a foreign corporation for the
transaction of business and is in good standing under the laws of
each other jurisdiction in which it owns or leases properties or
conducts any business so as to require such qualification, except
where the failure to be so qualified or in good standing under the
laws of such other jurisdiction would not, singly or in the
aggregate, have a material adverse effect on the Company and its
subsidiaries, taken as a whole;
|
|
|
(f)
|
Each subsidiary of the Company
(i) has been duly incorporated and is validly existing as a
corporation in good standing under the laws of its jurisdiction of
incorporation with power and authority (corporate and other) to own
its properties and conduct its business as described in the Pricing
Circular, and (ii) has been duly qualified as a foreign
corporation for the transaction of business and is in good standing
under the laws of each other jurisdiction in which it owns or
leases properties or conducts any business so as to require such
qualification, except where the failure to be so qualified or in
good standing under the laws of such other jurisdiction would not,
singly or in the aggregate, have a material adverse effect on the
Company and its subsidiaries, taken as a whole;
|
|
|
(g)
|
Gulf South Medical Supply, Inc.
is the only subsidiary of the Company that is a significant
subsidiary of the Company’s within the meaning of
Section 1-02(w) of Regulation S-X under the Securities Act of
1933, as amended (the “Act”);
|
|
|
(h)
|
The Company has an authorized
capitalization as set forth in the Pricing Circular, and all of the
issued shares of capital stock of the Company have been duly and
validly authorized and issued and are fully paid and
non-assessable; the shares of Stock initially issuable upon
conversion of the Securities have been duly and validly authorized
and reserved for issuance and, when issued and delivered in
accordance with the provisions of the Securities and the Indenture
referred to below, will be duly and validly issued, fully paid and
non-assessable and will conform to the description of the Stock
contained in the Pricing
|
3
|
|
Disclosure Package and the
Offering Circular; and all of the issued shares of capital stock of
each subsidiary of the Company have been duly and validly
authorized and issued, are fully paid and non-assessable and
(except for directors’ qualifying shares) are owned directly
or indirectly by the Company, free and clear of all liens,
encumbrances, equities or claims except as set forth in the Pricing
Circular;
|
|
|
(i)
|
The Securities have been duly
authorized by the Company and, when issued and delivered pursuant
to this Agreement, when authenticated by the Trustee in accordance
with the Indenture (as defined below), and when paid for by the
Purchaser in accordance with the terms hereof, will have been duly
executed, authenticated, issued and delivered and will constitute
valid and legally binding obligations of the Company entitled to
the benefits provided by the indenture to be dated as of
August 4, 2008 (the “Indenture”) between the
Company and U.S. Bank National Association, as Trustee (the
“Trustee”), under which they are to be issued and will
be convertible into Stock in accordance with their terms and the
Indenture; the Securities will rank equal in right of payment with
all of the Company’s other unsecured and unsubordinated
indebtedness; the Indenture has been duly authorized and, when
executed and delivered by the Company and the Trustee, the
Indenture will constitute a valid and legally binding instrument of
the Company, enforceable against the Company in accordance with its
terms, subject, as to enforcement, to bankruptcy, insolvency,
reorganization and other laws of general applicability relating to
or affecting creditors’ rights and to general equitable
principles (regardless of whether such enforcement is considered in
a proceeding at law or in equity); and the Securities and the
Indenture will conform to the descriptions thereof in the Pricing
Disclosure Package and the Offering Circular and will be in
substantially the form previously delivered to you;
|
|
|
(j)
|
This Agreement has been duly
authorized, executed and delivered by the Company;
|
|
|
(k)
|
None of the transactions
contemplated by this Agreement (including, without limitation, the
use of the proceeds from the sale of the Securities) will violate
or result in a violation of Section 7 of the Exchange Act, or
any regulation promulgated thereunder, including, without
limitation, Regulations T, U, and X of the Board of Governors of
the Federal Reserve System;
|
|
|
(l)
|
Prior to the date hereof, neither
the Company nor any of its “affiliates” (as defined in
Rule 144 under the Act) has taken any action that is
prohibited by Section 9(a) of the Exchange Act or any
applicable state securities laws;
|
|
|
(m)
|
The issue and sale of the
Securities and the compliance by the Company with all of the
provisions of the Securities, the Indenture and this Agreement and
the consummation of the transactions herein and therein
contemplated (including, without limitation, the use of proceeds
from the sale of the Securities) will not conflict with or result
in a breach or violation of any of the terms or provisions of, or
constitute a default under, any indenture, mortgage, deed of trust,
loan agreement or other agreement or instrument to which the
Company or any of its subsidiaries is a party or by which the
Company or any of its subsidiaries is bound or to which any of the
property or assets of the Company or any of its subsidiaries is
subject except for such conflicts, breaches or violations which
would not, singly or in the aggregate, have a material adverse
effect on the Company and its subsidiaries, taken as a whole, nor
will such action result in any violation of the provisions
of
|
4
|
|
the Articles of Incorporation or
By-laws of the Company or any statute or any order, rule or
regulation of any court or governmental agency or body having
jurisdiction over the Company or any of its subsidiaries or any of
their properties; and no consent, approval, authorization, order,
registration or qualification of or with any such court or
governmental agency or body is required for the issue and sale of
the Securities or the consummation by the Company of the
transactions contemplated by this Agreement or the Indenture,
except such consents, approvals, authorizations, registrations or
qualifications as may be required under state securities or Blue
Sky laws in connection with the purchase and distribution of the
Securities by the Purchaser;
|
|
|
(n)
|
Neither the Company nor any of
its subsidiaries (i) is in violation of its Articles of
Incorporation or By-laws or (ii) in default in the performance
or observance of any obligation, covenant or condition contained in
any indenture, mortgage, deed of trust, loan agreement, lease or
other agreement or instrument to which it is a party or by which it
or any of its properties may be bound, except for such defaults
that would not, singly or in the aggregate, have a material adverse
effect on the Company and its subsidiaries, taken as a
whole;
|
|
|
(o)
|
The statements set forth in the
Pricing Circular and the Offering Circular under the caption
“Description of Notes” and “Description of
Capital Stock”, insofar as they purport to constitute a
summary of the terms of the Securities and the Stock, under the
caption “Certain United States Federal Income Tax
Considerations”, and under the caption “Plan of
Distribution”, insofar as they purport to describe the
provisions of the laws and documents referred to therein, are
accurate and complete in all material respects;
|
|
|
(p)
|
Other than as set forth in the
Pricing Circular, there are no legal or governmental proceedings
pending nor, to the knowledge of the Company, threatened, to which
the Company or any of its subsidiaries is or would be a party or of
which any property of the Company or any of its subsidiaries is or
would be the subject which, if determined adversely to the Company
or any of its subsidiaries, would individually or in the aggregate
have a material adverse effect on the current or future financial
position, shareholders’ equity or results of operations of
the Company and its subsidiaries or on the power or ability of the
Company to perform its obligations under this Agreement, the
Indenture or the Securities or to consummate the transactions
contemplated herein and therein;
|
|
|
(q)
|
The Company and its subsidiaries
(i) are in compliance with any and all applicable foreign
federal, state and local laws and regulations relating to the
protection of human health and safety, the environment or hazardous
or toxic substances or wastes, pollutants or contaminants
(“Environmental Laws”), (ii) have received all
permits, licenses or other approvals required of them under
applicable Environmental Laws to conduct their respective
businesses and (iii) are in compliance with all terms and
conditions of any such permit, license or approval, except where
such noncompliance with Environmental Laws, failure to receive
required permits, licenses or other approvals or failure to comply
with the terms and conditions of such permits, licenses or
approvals would not, singly or in the aggregate, have a material
adverse effect on the Company and its subsidiaries, taken as a
whole;
|
|
|
(r)
|
There are no costs or liabilities
associated with Environmental Laws (including, without limitation,
any capital or operating expenditures required for clean-up,
closure of properties or compliance with Environmental Laws or any
permit, license or approval, any related
|
5
|
|
constraints on operating
activities and any potential liabilities to third parties) which
would, singly or in the aggregate, have a material adverse effect
on the Company and its subsidiaries, taken as a whole;
|
|
|
(s)
|
When the Securities are issued
and delivered pursuant to this Agreement, the Securities will not
be of the same class (within the meaning of Rule 144A under the
Act) as securities which are listed on a national securities
exchange registered under Section 6 of the Exchange Act or
quoted in a U.S. automated inter-dealer quotation
system;
|
|
|
(t)
|
The Company is subject to
Section 13 or 15(d) of the Exchange Act;
|
|
|
(u)
|
The Company is not, and after
giving effect to the offering and sale of the Securities and the
application of the net proceeds thereof, will not be an
“investment company”, as such term is defined in the
United States Investment Company Act of 1940, as amended (the
“Investment Company Act”);
|
|
|
(v)
|
Neither the Company, any of its
affiliates nor any person acting on its or their behalf has offered
or sold the Securities by means of any general solicitation or
general advertising within the meaning of Rule 502(c) under the
Act;
|
|
|
(w)
|
Within the preceding six months,
neither the Company, any of its affiliates nor any other person
acting on its or their behalf has offered or sold to any person any
Securities, or any securities of the same or a similar class as the
Securities, other than Securities offered or sold to the Purchaser
hereunder. The Company will take reasonable precautions designed to
insure that any offer or sale, direct or indirect, in the United
States or to any U.S. person (as defined in Rule 902 under the Act)
of any Securities or any substantially similar security issued by
the Company, within six months subsequent to the date on which the
distribution of the Securities has been completed (as notified to
the Company by the Purchaser), is made under restrictions and other
circumstances reasonably designed not to affect the status of the
offer and sale of the Securities in the United States and to U.S.
persons contemplated by this Agreement as transactions exempt from
the registration provisions of the Act;
|
|
|
(x)
|
KPMG LLP, which has audited
certain financial statements of the Company and its subsidiaries
and has audited the Company’s internal control over financial
reporting, is an independent registered public accounting firm as
required by the Act and the rules and regulations of the Commission
thereunder;
|
|
|
(y)
|
It is not necessary in connection
with the offer, sale and delivery of the Securities to the
Purchaser in the manner contemplated by this Agreement to register
the Securities under the Act or to qualify the Indenture under the
Trust Indenture Act of 1939, as amended;
|
|
|
(z)
|
The Company and its subsidiaries
have and will maintain insurance covering their respective
properties, operations, personnel and businesses, which insurance
is in amounts and insures against such losses and risks, in each
case as the Company believes is in accordance with customary
industry practice for companies of similar size and operations,
except where the failure to maintain such insurance would not,
singly or in the aggregate, have a material adverse effect on the
Company and its subsidiaries, taken as a whole;
|
6
|
|
(aa)
|
The Company and each of its
subsidiaries possess all licenses, certificates, approvals and
permits issued by, and has made all declarations and filings with,
the appropriate federal, state or foreign regulatory agencies or
bodies (including, without limitation, the Federal Food and Drug
Administration, the Federal Drug Enforcement Administration and
comparable state agencies) necessary for the ownership of the
Company’s and its subsidiaries’ properties or the
conduct of its and their businesses (including, without limitation,
the marketing of the products that the Company and its subsidiaries
currently market) as described in the Pricing Circular, except
where the failure to possess or make the same would not, singly or
in the aggregate, have a material adverse effect on the Company and
its subsidiaries, taken as a whole; and none of the Company or its
subsidiaries have received notification of any revocation or
modification of any such license, certificate, authorization or
permit where the revocation or modification would result in a
material adverse effect on the Company and its subsidiaries, taken
as a whole, or have any reason to believe that any such license,
certificate, authorization or permit will not be renewed where the
failure to renew would have a material adverse effect on the
Company and its subsidiaries, taken as a whole;
|
|
|
(bb)
|
The Company maintains a system of
internal control over financial reporting (as such term is defined
in Rule 13a-15(f) of the Exchange Act) that complies with the
requirements of the Exchange Act and has been designed by the
Company’s principal executive officer and principal financial
officer, or under their supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. The
Company’s internal control over financial reporting is
effective and the Company is not aware of any material weaknesses
in its internal control over financial reporting;
|
|
|
(cc)
|
Since the date of the latest
audited financial statements included or incorporated by reference
in the Pricing Circular, there has been no change in the
Company’s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect,
the Company’s internal control over financial reporting;
and
|
|
|
(dd)
|
The Company maintains disclosure
controls and procedures (as such term is defined in
Rule 13a-15(e) of the Exchange Act) that comply with the
requirements of the Exchange Act; such disclosure controls and
procedures have been designed to ensure that material information
relating to the Company and its subsidiaries is made known to the
Company’s principal executive officer and principal financial
officer by others within those entities; and such disclosure
controls and procedures are effective.
|
|
2.
|
Subject to the terms and
conditions herein set forth, the Company agrees to issue and sell
to the Purchaser, and the Purchaser agrees to purchase from the
Company, at a purchase price of 98.00% of the principal amount
thereof, the Firm Securities.
|
The Company hereby grants to the
Purchaser the right to purchase at its election up to $30,000,000
aggregate principal amount of Optional Securities, at the purchase
price for the Firm Securities set forth in the first paragraph of
this Section 2. Any such election to purchase Optional
Securities may be exercised in whole or from time to time in part
by written notice from you to the Company, setting forth the
aggregate principal amount of Optional Securities to be purchased
and the date on which such Optional Securities are to be delivered,
as determined by
7
you but in no event earlier than the
First Time of Delivery (as defined in Section (4) hereof) or,
unless you and the Company otherwise agree in writing, earlier than
two or later than ten business days after the date of such
notice.
|
3.
|
Upon the authorization by you of
the release of the Securities, the Purchaser proposes to offer the
Securities for sale upon the terms and conditions set forth in this
Agreement and the Offering Circular and the Purchaser hereby
represents and warrants to, and agrees with, the Company
that:
|
|
|
(a)
|
It will offer and sell the
Securities only to persons who it reasonably believes are
“qualified institutional buyers” (“QIBs”)
within the meaning of Rule 144A under the Act in transactions
meeting the requirements of Rule 144A;
|
|
|
(b)
|
It is an institutional accredited
investor as set forth in subsections (1), (2), (3) or
(7) of Rule 501(a) under the Act; and
|
|
|
(c)
|
It will not offer or sell the
Securities by any form of general solicitation or general
advertising, including but not limited to the methods described in
Rule 502(c) under the Act.
|
|
|
|
|
|
|
|
4.
|
|
(a)
|
|
The Securities to be purchased by
the Purchaser hereunder will be represented by one or more
definitive global Securities in book-entry form which will be
deposited by or on behalf of the Company with The Depository Trust
Company (“DTC”) or its designated custodian. The
Company will deliver the Securities to the Purchaser against
payment by the Purchaser of the purchase price therefor by wire
transfer to an account designated by the Company in Federal (same
day) funds, by causing DTC to credit the Securities to the account
of the Purchaser. The Company will cause the certificates
representing the Securities to be made available for checking at
least twenty-four hours prior to the Time of Delivery (as defined
below) at the office of Cleary Gottlieb Steen & Hamilton
LLP, One Liberty Plaza, New York, NY 10006 (the “Closing
Location”). The time and date of such delivery and payment
shall be 9:30 a.m., New York City time, on August 4, 2008 or
such other time and date as the Purchaser and the Company may agree
upon in writing and, with respect to the Optional Securities, 9:30
a.m., New York City time, on the date specified in the written
notice given by the Purchaser of its election to purchase such
Optional Securities, or such other time and date as the Purchaser
and the Company may agree upon in writing, provided that any
Subsequent Time of Delivery (as defined below), if any, shall not
be more than 30 calendar days from and including the First Time of
Delivery (as defined below). The time and date for delivery of the
Firm Securities is herein called the “First Time of
Delivery”, the time and date for delivery of any Optional
Securities, if not the First Time of Delivery, is herein called the
“Subsequent Time of Delivery”, and each such time and
date for delivery is herein called a “Time of
Delivery”.
|
|
|
(b)
|
The documents to be delivered at
the Time of Delivery by or on behalf of the parties her
|
|